FDA-Cleared AI Device

Canvas Dx

Cognoa

Combines caregiver questionnaires, video of the child, and clinician input into an algorithmic diagnostic aid for autism spectrum disorder in children aged 18 months to 6 years.

At A Glance

Manufacturer
Cognoa
Medical specialty
Psychiatry and Behavioral Health
Clearance route
De Novo
Year authorized
2021
Modality
Multi-source behavioral data
Role in workflow
Diagnostic aid

The bottleneck in autism diagnosis is not diagnostic difficulty for a specialist. It is that specialist waitlists routinely run past a year, during which the intervention window that matters most is closing. A device that lets a primary care clinician reach a supported determination is attacking the waitlist, not the diagnostic accuracy.

Where It Is Used

  • Autism diagnostic support in primary care
  • Reducing time to diagnosis where specialist waitlists are long
  • Structured assessment without a developmental specialist

Limitations Worth Knowing

The device returns positive, negative, or indeterminate, and the indeterminate rate is not small. Those children still need specialist assessment. Performance was established in a specific age band, and it is a diagnostic aid, not a diagnosis.

Regulatory status, indications, and labeling change over time. Confirm current status on the FDA's AI/ML-Enabled Medical Devices list and in the manufacturer's current instructions for use before relying on anything stated here.